John Parkinson

A sub-analysis of phase 2 data compared the immunogenicity of their VLA15 vaccine in adults after administration of 2 or 3 primary series doses with the latter demonstrating a stronger response.

The company’s Spikvax vaccine was approved based on its submission that included efficacy and safety data approximately 6 months after second dose.

Company announced it had administered its first shot to a participant for its extension of an earlier phase 2 study.

The companies said the vaccines will be examined in adults 18-55 years old.

More than 1.2 million people were estimated to have died in 2019 as a direct result, and that antimicrobial-resistant infections played a role in millions more.

In utilizing a modeling study, investigators estimated reductions in HIV incidence rates as well as PrEP usage rates and viral suppression across US cities over 10 years.

A predictive tool, POC Advisor, has been developed to support faster diagnosis and intervention of this dangerous condition.

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.

The award given to the research institute by the state of Pennsylvania looks to delve deep in understanding vulnerable populations and taking some lessons away in addressing future potential pandemics.

The Advisory Committee on Immunization Practices (ACIP) voted yes to a third shot of the Pfizer-BioNTech COVID-19 vaccine in this pediatric population.

A pregnant woman is reported to be the country’s first person to be infected simultaneously with COVID-19 and influenza.

The country says one city hospital’s data shows a decrease in severity and mortality during this latest variant's outbreak.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP are aiming to increase users.

This is the first pill to treat COVID-19 in trying to prevent progression to severe disease and possible hospitalization.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

The therapy becomes the first injectable approved in the United States for this indication.

The proposed funding will include a number of measures of spending towards HIV and prevention, including community centers for PrEP education.

The website, LearnAntibiotics.com, is a supplemental tool offering guides, practice exams, and other resources to help students, residents, or practicing professionals with infectious diseases pharmacotherapy.

The company believes the pill should work against the Omicron variant.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

The strategies address booster doses, travel, and rapid response.

The first Omicron COVID-19 case was discovered in California. The patient, who traveled from South Africa, has since recovered.

As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.

Moderna and Pfizer's CEOs voice doubt on the current vaccines’ efficacy with the new variant, but are developing prophylaxis vaccines and treatment strategies to curtail the new strain.

The strain identified as B.1.1.529 is causing some travel restrictions from some African countries, and medical science is rushing to understand its potential impact on the global stage.

HIV Stakeholders weigh on the future of PrEP.

The federal agency's decision makes this the first CMV treatment for this patient population.